- Integration delivers a holistic, software-based remote diagnostic test for total workplace health and wellbeing management – offering is a world first for corporates
- WMA is a leading healthcare solutions company providing holistic health and wellbeing management solutions to corporate clients across a range of industry sectors
- ResApp to receive a monthly fee for every worker that WMA’s Medetective service covers under gold and platinum subscription tiers which include access to on-demand telehealth medical consultations
- Agreement delivers ResApp access to new sectors with large workforces including financial services, mining and construction, amongst others
Brisbane, Australia, 19 November 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise it has signed a non-exclusive, two-year software licensing agreement with healthcare solutions provider Workplace Medicine Australia Ltd (“WMA”), to integrate ResApp’s acute respiratory diagnostic test ResAppDx, in WMA’s upcoming fully integrated and holistic workplace health and wellbeing management application, Medetective (www.medetective.com.au).
WMA focuses on implementing state-of-the-art, evidence-based healthcare solutions to raise the standard for workplace health and wellbeing management, to ensure a healthy workforce and strengthen productivity within organisations. The group provides holistic medical screening and consultation services for corporate clients across a range of different industries including financial services, insurance, mining and construction.
WMA will integrate ResAppDx into its new Medetective app, for use as a remote respiratory diagnostic aid alongside a telehealth consultation, reducing the need for employees to book in and travel to see a clinician for diagnosis. ResAppDx will be made available under the Medetective gold and platinum pricing tiers, which include on-demand telehealth medical consultations.
ResAppDx uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone’s built-in microphone. It is CE Marked in Europe and TGA approved in Australia.
ResAppDx will now be integrated into the Medetective application, which is set to launch in February 2021. The two-year licence will commence from the launch date. Under the agreement, ResApp will receive a monthly fee for every worker that WMA’s gold or platinum service covers at a client workplace. While revenue from the agreement cannot be estimated at this early stage and is dependent on the number of clients signing up to WMA’s gold and platinum pricing tiers, ResApp remains confident of significant commercial uptake.
The licence agreement may be extended beyond the initial two-year term by mutual agreement. Either party may terminate the licence by providing 60 days written notice.
CEO and Managing Director Dr Tony Keating said: “As the adoption of telehealth continues in Australia, ResApp is witnessing increased interest in its software solutions. The company will look to capitalise on this in the near term, further diversifying its partnerships across industries to create a solid foundation for growth.
“This agreement with WMA is very important, as it considerably broadens the company’s visibility into new, large sectors with substantial workforces. We are confident that ResAppDx will greatly assist in the diagnosis of respiratory disease, before it becomes an issue in workplaces.”
Medical Director and Co-Founder of WMA Dr Scott Allison said: “WMA has medical and engineering capabilities to allow its clients to better assess and manage risk as well as maintain a healthy workforce. With the future workplace continually adapting to drive and embrace a health focused culture, we have developed our Medetective platform to facilitate on-demand preventative medical support for organisations, informed by an array of remote medical diagnostic tools. ResAppDx will enable our clinicians to better assess respiratory symptoms when diagnosing patients remotely through our world-first, holistic health management platform, Medetective.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.
About Workplace Medicine Ltd
Workplace Medicine Australia (WMA) was created by medical professionals with the aim of implementing state-of-the-art, evidence-based healthcare solutions to ensure a healthy workforce and enhance capability within organisations. WMA’s Medical Director, Dr. Scott Allison, is a Specialist General Practitioner with a special interest in workplace medicine, having worked in healthcare delivery across public, private and defence sectors. WMA ensures the workplace health solutions implemented within your organisation are in-line with best medical practice and constantly evolving government recommendations.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.